Preliminary results from several different B7-H3-based cancer immunotherapy strategies in NSCLC come mainly from antibody–drug conjugates, mAbs mediating cellular cytotoxicity, and CD3-engaging bispecific antibodies strategic approaches. The gene discussed is CD276; the disease is cancer.